RedHill Biopharma (RDHL) Total Liabilities (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Total Liabilities data on file, last reported at $21.1 million in Q4 2025.

• On a quarterly basis, Total Liabilities fell 7.26% year-over-year to $21.1 million in Q4 2025; TTM through Dec 2025 was $21.1 million, a 7.26% decrease from a year earlier, with the FY2025 full-year figure at $21.1 million, down 7.26% from the prior year.
• Total Liabilities for Q4 2025 stood at $21.1 million, down from $22.8 million in the prior quarter.
• Over the last five years, Total Liabilities for RDHL reached as high as $203.2 million in Q3 2022 and fell as low as $741000.0 in Q4 2023.
• Historically, Total Liabilities has averaged $94.9 million across 5 years, with a median of $56.8 million in 2023.
• Across the five-year window, Total Liabilities tumbled 98.48% in 2022 and surged 2966.94% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $172.3 million in 2021, then tumbled by 98.48% to $2.6 million in 2022, then sank by 71.75% to $741000.0 in 2023, then jumped by 2966.94% to $22.7 million in 2024, then declined by 7.26% to $21.1 million in 2025.
• Per Business Quant data, the three most recent Total Liabilities figures were $21.1 million in Q4 2025, $22.8 million in Q2 2025, and $22.7 million in Q4 2024.